![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF260 |
Gene summary for ZNF260 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF260 | Gene ID | 339324 |
Gene name | zinc finger protein 260 | |
Gene Alias | OZRF1 | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q3ZCT1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
339324 | ZNF260 | HCC1_Meng | Human | Liver | HCC | 2.14e-21 | 1.08e-02 | 0.0246 |
339324 | ZNF260 | HCC2_Meng | Human | Liver | HCC | 2.02e-05 | -1.38e-02 | 0.0107 |
339324 | ZNF260 | HCC1 | Human | Liver | HCC | 1.37e-10 | 3.15e+00 | 0.5336 |
339324 | ZNF260 | HCC2 | Human | Liver | HCC | 7.86e-18 | 3.63e+00 | 0.5341 |
339324 | ZNF260 | S028 | Human | Liver | HCC | 6.00e-07 | 3.75e-01 | 0.2503 |
339324 | ZNF260 | S029 | Human | Liver | HCC | 4.21e-08 | 3.76e-01 | 0.2581 |
339324 | ZNF260 | male-WTA | Human | Thyroid | PTC | 9.70e-03 | 4.47e-02 | 0.1037 |
339324 | ZNF260 | PTC05 | Human | Thyroid | PTC | 2.81e-03 | 1.55e-01 | 0.2065 |
339324 | ZNF260 | PTC06 | Human | Thyroid | PTC | 2.25e-10 | 2.04e-01 | 0.2057 |
339324 | ZNF260 | PTC07 | Human | Thyroid | PTC | 5.44e-11 | 1.18e-01 | 0.2044 |
339324 | ZNF260 | ATC13 | Human | Thyroid | ATC | 1.88e-99 | 1.92e+00 | 0.34 |
339324 | ZNF260 | ATC2 | Human | Thyroid | ATC | 4.52e-04 | 6.22e-01 | 0.34 |
339324 | ZNF260 | ATC5 | Human | Thyroid | ATC | 4.00e-104 | 2.02e+00 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF260 | SNV | Missense_Mutation | c.101N>C | p.Lys34Thr | p.K34T | Q3ZCT1 | protein_coding | deleterious(0) | benign(0.356) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ZNF260 | SNV | Missense_Mutation | rs749233923 | c.944G>A | p.Arg315Gln | p.R315Q | Q3ZCT1 | protein_coding | tolerated(1) | benign(0.018) | TCGA-F5-6864-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
ZNF260 | SNV | Missense_Mutation | novel | c.21T>G | p.Ser7Arg | p.S7R | Q3ZCT1 | protein_coding | deleterious(0) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZNF260 | SNV | Missense_Mutation | rs775783148 | c.746N>T | p.Thr249Met | p.T249M | Q3ZCT1 | protein_coding | deleterious(0.02) | benign(0.239) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF260 | SNV | Missense_Mutation | novel | c.1118C>T | p.Ser373Leu | p.S373L | Q3ZCT1 | protein_coding | deleterious(0.03) | possibly_damaging(0.852) | TCGA-AJ-A2QM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
ZNF260 | SNV | Missense_Mutation | c.1075N>A | p.Pro359Thr | p.P359T | Q3ZCT1 | protein_coding | deleterious(0.01) | possibly_damaging(0.635) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF260 | SNV | Missense_Mutation | c.373N>G | p.Arg125Gly | p.R125G | Q3ZCT1 | protein_coding | tolerated(0.29) | benign(0.057) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF260 | SNV | Missense_Mutation | c.939N>A | p.Phe313Leu | p.F313L | Q3ZCT1 | protein_coding | deleterious(0) | benign(0.266) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
ZNF260 | SNV | Missense_Mutation | rs775467971 | c.959T>C | p.Ile320Thr | p.I320T | Q3ZCT1 | protein_coding | tolerated(0.29) | benign(0.007) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF260 | SNV | Missense_Mutation | novel | c.854T>C | p.Phe285Ser | p.F285S | Q3ZCT1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |